Soha Ismai | Pharmacology, Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

Posted on by ScienceFather

Assist Prof Dr. Soha Ismai | Pharmacology, Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

Assistant Professor, EDA, Egypt

With a solid foundation in pharmacy, including a Bachelor’s, Master’s, and PhD from Cairo University, and a position as Associate Professor, this individual demonstrates exceptional expertise. Their diverse professional experience spans quality control, management, and academic roles, showcasing their leadership and practical knowledge in the pharmaceutical field. Their prolific research output includes numerous publications on advanced drug delivery systems and nanotechnology, reflecting significant contributions to pharmaceutical sciences. Active participation in various training courses, workshops, and international conferences highlights their commitment to continuous professional development. Additionally, their multilingual skills enhance their ability to collaborate in diverse settings. Overall, their comprehensive background in education, research, and professional development, combined with their active engagement in the scientific community, makes them a highly suitable candidate for the Best Researcher Award.

Education

The candidate has a robust educational background that serves as the foundation of their expertise in the field of pharmaceutical sciences. They earned a Bachelor of Pharmacy degree from Cairo University in 1996, graduating with honors, which set the stage for their academic and professional journey. Their pursuit of advanced knowledge led them to complete a Master’s degree in Pharmaceutics in 2007 and later a PhD in 2011, both from the same esteemed institution. This rigorous academic training has equipped them with in-depth knowledge of pharmaceutics, drug formulation, and pharmaceutical analysis. In 2019, they further solidified their academic credentials by attaining the position of Associate Professor, demonstrating their commitment to education, research, and mentorship. Their continuous academic progression reflects a strong commitment to excellence and a desire to contribute significantly to the pharmaceutical sciences, positioning them as a thought leader in their field and a prime candidate for the Best Researcher Award.

Profesional Experience

The candidate has an extensive professional background in the pharmaceutical sector, beginning their career as a QC analyst for raw materials at NODCAR from 1996 to 1999. They then transitioned to academia as a teaching assistant at the Faculty of Pharmacy, October University, in 1999. Between 2000 and 2012, they worked as a QC analyst specializing in physical properties before moving into management roles, including quality manager and deputy lab manager. From 2016 to 2021, they served as a technical manager, demonstrating their expertise in overseeing laboratory operations and maintaining quality standards. Their role expanded further as they joined several committees, contributing to updating pharmaceutical guidelines and developing the Egyptian pharmacopeia. In 2021, they became the lab manager of the physicochemical lab at the Egyptian Drug Authority (EDA), where they continue to lead and innovate in quality control and research.

Research Skill

The candidate possesses exceptional research skills, demonstrated through a prolific publication record in high-impact journals and extensive experience in developing innovative pharmaceutical formulations. They have expertise in designing and conducting complex experimental studies, including the use of advanced methodologies like Box–Behnken design for optimization and in vivo evaluations. Their research work spans various domains, including nanotechnology, ocular drug delivery, and gastroretentive systems, showcasing versatility and a strong ability to adapt to emerging scientific trends. Additionally, their role in supervising master’s and PhD theses highlights their leadership in guiding future researchers. The candidate is also well-versed in utilizing statistical analysis tools and quality-by-design approaches, which are critical for ensuring the rigor and reliability of research findings. Their ability to translate research into practical applications, coupled with active participation in committees that shape pharmaceutical guidelines, underscores a profound impact on both academic and industry standards in the pharmaceutical sciences.

Awards And Recoginition

The individual has received multiple accolades throughout their career, reflecting their outstanding contributions to the field of pharmaceutical sciences. Their expertise in pharmaceutics and dedication to research have been recognized by esteemed institutions and professional bodies. Notably, they have been honored for their innovative work in drug delivery systems and quality management, which have had a significant impact on the pharmaceutical industry. They have been a valuable member of committees responsible for updating pharmaceutical guidelines and establishing national standards, further highlighting their influence and leadership in the field. Additionally, their research publications in renowned international journals have been widely cited, earning them recognition among peers as a leading researcher. Their participation in prestigious conferences and workshops, both as a presenter and a participant, underscores their commitment to continuous learning and sharing knowledge. These recognitions affirm their position as a distinguished professional dedicated to advancing pharmaceutical science and improving healthcare outcomes.

Conclution

The individual’s blend of academic excellence, practical experience, prolific research output, and continuous professional growth makes them a highly suitable candidate for the Best Researcher Award. Their achievements reflect their dedication to advancing pharmaceutical science and their impact on the field.

Publication Top Notes

  1. Enhanced wound healing activity of naturally derived Lagenaria siceraria seed oil binary nanoethosomal gel: formulation, characterization, in vitro/in vivo efficiency
    • Authors: Nagham H. Kamal, Fatema R. Saber, Abeer Salama, Dalia M. N. Abouhussein, Soha Ismail, Hala M. El-Hefnawy, Meselhy R. Meselhy
    • Year: 2024
    • Citation: Kamal NH, Saber FR, Salama A, Abouhussein DMN, Ismail S, El-Hefnawy HM, Meselhy MR. Enhanced wound healing activity of naturally derived Lagenaria siceraria seed oil binary nanoethosomal gel: formulation, characterization, in vitro/in vivo efficiency. Future Journal of Pharmaceutical Sciences. 2024 Aug 19. doi:10.1186/s43094-024-00678-2.
  2. Mucoadhesive Chitosan Composite Sponge as a Carrier for β-Sitosterol Cubosomes for Thermal Burn Treatment
    • Authors: Abeer Khattab, Soha Ismail, Areeg M. Abd-Elrazek
    • Year: 2024
    • Citation: Khattab A, Ismail S, Abd-Elrazek AM. Mucoadhesive Chitosan Composite Sponge as a Carrier for β-Sitosterol Cubosomes for Thermal Burn Treatment. AAPS PharmSciTech. 2024 Jun 27. doi:10.1208/s12249-024-02852-4.
  3. Optimization of topical curcumin spanlastics for melanoma treatment
    • Authors: Soha Ismail, Doaa Garhy, Howida K. Ibrahim
    • Year: 2023
    • Citation: Ismail S, Garhy D, Ibrahim HK. Optimization of topical curcumin spanlastics for melanoma treatment. Pharmaceutical Development and Technology. 2023 May 28. doi:10.1080/10837450.2023.2204926.
  4. Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: optimization using Box–Behnken design and in vivo evaluation
    • Authors: Marwa H. Shukr, Soha Ismail, Ghada G. El-Hossary, Amany H. El-Shazly
    • Year: 2022
    • Citation: Shukr MH, Ismail S, El-Hossary GG, El-Shazly AH. Spanlastics nanovesicular ocular insert as a novel ocular delivery of travoprost: optimization using Box–Behnken design and in vivo evaluation. Journal of Liposome Research. 2022 Oct 2. doi:10.1080/08982104.2022.2025828.
  5. Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI
    • Authors: Marwa Farrag Abd El-Aziz, Soha Ismail, Mina Ibrahim Tadros, Mohamed Ahmed Elnabarawi
    • Year: 2020
    • Citation: Abd El-Aziz MF, Ismail S, Tadros MI, Elnabarawi MA. Alfuzosin hydrochloride-loaded low-density gastroretentive sponges: development, in vitro characterization and gastroretentive monitoring in healthy volunteers via MRI. Pharmaceutical Development and Technology. 2020 May 27. doi:10.1080/10837450.2020.1720235.
  6. Development and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity
    • Authors: Marwa H. Shukr, Soha Ismail, Samya Mahmoud Ahmed
    • Year: 2019
    • Citation: Shukr MH, Ismail S, Ahmed SM. Development and optimization of ezetimibe nanoparticles with improved antihyperlipidemic activity. Journal of Drug Delivery Science and Technology. 2019 Feb. doi:10.1016/j.jddst.2018.12.001.
  7. Butoconazole nitrate vaginal sponge: Drug release and antifungal efficacy
    • Authors: Dalia S. Shaker, Soha Ismail, Selwan Hamed, Eman M. El-Shishtawy
    • Year: 2018
    • Citation: Shaker DS, Ismail S, Hamed S, El-Shishtawy EM. Butoconazole nitrate vaginal sponge: Drug release and antifungal efficacy. Journal of Drug Delivery Science and Technology. 2018 Dec. doi:10.1016/j.jddst.2018.09

 

Alaa Alsalloum | Immunology and Microbiology | Excellence in Research

Posted on by ScienceFather

 Dr. Alaa Alsalloum | Immunology and Microbiology | Excellence in Research

Dr. Alaa Alsalloum, Novosibirsk State University, Russia.

Dr. Alaa Alsalloum is a dedicated researcher in the fields of immunology and microbiology, known for her contributions to understanding immune responses and microbial interactions. With a strong commitment to excellence in research, she focuses on innovative approaches to tackle infectious diseases and enhance immunological health. Alaa’s work is characterized by a collaborative spirit and a passion for advancing scientific knowledge, making her a valuable asset in the pursuit of breakthroughs in health and disease management.

Profile:

Education

Alaa Alsalloum’s educational journey began at the National Center for Distinguished in Syria, where she completed high school from October 2011 to June 2014. She then earned her Bachelor of Science in Pharmacy from the University of Damascus, focusing on Biomedical Sciences, with a thesis titled “Phage Nanobody Immuno-PCR for Ultra-sensitive Detection of Growth Hormone (GH).” Following this, Alaa participated in a general education program at Kazan (Volga Region) Federal University to master professional educational programs in Russian from October 2018 to June 2019. She continued her studies at Kazan Federal University, where she completed her master’s degree in the Institute of Medicine and Biology, focusing on the earlier immune markers of multiple sclerosis in an animal model for her thesis. Currently, Alaa is pursuing her PhD at Novosibirsk State University, specializing in molecular immunology, with her research centered on the phenotypic and functional characteristics of T-lymphocytes with genetically modified antigen-recognizing receptors specific to solid tumor antigens.

 Interests

Alaa Alsalloum is committed to community service, having volunteered with the Association for Persons with Special Needs (APSN) in Deir Atiyah, Syria, from July 2014 to September 2015. During her time there, she contributed to supporting individuals with special needs, helping to enhance their quality of life and promote inclusivity. This experience reflects her dedication to making a positive impact in the lives of others and highlights her passion for service beyond her academic pursuits.

 Skills

Alaa Alsalloum possesses a robust set of technical skills acquired through her research in immunology and molecular biology during her Bachelor’s and Master’s theses. She is proficient in DNA and RNA extraction, PCR, electrophoresis, bacterial transformation, ELISA tests, immunochemistry, NanoString technology, and cell culture techniques. Additionally, she has experience with PBMC isolation, viral transduction of T-lymphocytes, dendritic cell differentiation protocols, tetramer assays, cell sorting protocols, flow cytometry, and intracellular flow cytometry staining. Alaa also has foundational knowledge in RT-PCR, cell analysis, Seahorse technology, 3D cell culture, and single-cell sequencing.On the interpersonal side, she has developed strong presentation and communication skills through participation in various seminars focused on communication and leadership. Alaa is adept at collaborating within a team while also demonstrating the ability to work independently, making her a well-rounded candidate in both research and professional settings.

 

Publication Top Notes

Alsalloum, A. (2024). NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapy. Clinical and Translational Medicine. DOI: 10.1002/ctm2.70020. ISSN: 2001-1326.

Alsalloum, A. (2023). TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors. Biomedicines, 11(10), Article 2805. DOI: 10.3390/biomedicines11102805.

Alsalloum, A. (2023). Exploring TCR-like CAR-Engineered Lymphocyte Cytotoxicity against MAGE-A4. International Journal of Molecular Sciences, 24(20), Article 15134. DOI: 10.3390/ijms242015134.

Alsalloum, A. (2023). Immunoregulatory properties of erythroid nucleated cells induced from CD34+ progenitors from bone marrow. PLOS ONE, 18(6), Article e0287793. DOI: 10.1371/journal.pone.0287793. ISSN: 1932-6203.

Alsalloum, A. (2023). The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy? Cancers, 15(6), Article 1779. DOI: 10.3390/cancers15061779.

Alsalloum, A. (2022). Phenotypic and functional features of in vitro generated TCR-T cells specific for the tumor-associated antigen NY-ESO-1. Immunologiya, 43(5), 536-547. DOI: 10.33029/0206-4952-2022-43-5-536-547.

Alsalloum, A. (2022). Study of MAGE-A4 specific TCR-like CAR-T lymphocytes in vitro. Immunologiya, 43(4), 401-411. DOI: 10.33029/0206-4952-2022-43-4-401-411.

Omar Ahmed-Farid | Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

Posted on by ScienceFather

Assoc Prof Dr. Omar Ahmed-Farid | Toxicology and Pharmaceutical Science | Life Sciences Innovation Award

2004, EDA, Egypt

Dr. Omar Abdel-Hamed Ahmed-Farid is a highly qualified candidate for the Research for Best Researcher Award. With a robust academic and professional background, Dr. Farid has significantly impacted the field of physiology and analytical chemistry. His impressive citation metrics—1889 citations, an H-index of 24, and an I10-index of 61—highlight his influential research. As the Unit Administration Manager at the Egyptian Drug Authority, he excels in regulatory compliance, quality assurance, and team leadership. His previous roles include Technical Manager and Drug Quality Control Specialist, where he managed laboratory practices and ensured adherence to international standards. Dr. Farid’s contributions to policy development and staff training further demonstrate his dedication to advancing industry standards and professional excellence. His extensive research experience, combined with his leadership in regulatory and quality assurance roles, makes him a strong contender for this award.

Profile:

Education

Dr. Omar Abdel-Hamed Ahmed-Farid has a distinguished educational trajectory that underscores his expertise in physiology and analytical chemistry. He began his academic journey as an Assistant Researcher in Physiology in 2005, gradually advancing through roles as an Assistant Researcher, Researcher, and ultimately becoming an Associate Professor of Physiology in 2020. His progression reflects a deepening of knowledge and a growing commitment to the field. Dr. Farid’s education has been marked by hands-on experience and rigorous training in high-performance analytical techniques, such as High-Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC). This solid educational foundation has been instrumental in his success in research, quality assurance, and regulatory compliance within the pharmaceutical and medical diagnostics sectors. His academic background is a testament to his dedication to advancing scientific knowledge and improving industry standards

Professional Experience

Dr. Omar Abdel-Hamed Ahmed-Farid’s professional experience showcases a profound impact on the fields of physiology and analytical chemistry. As the Unit Administration Manager of Diagnostic Kits and Medical Supplies at the Egyptian Drug Authority (EDA), he oversees regulatory compliance, quality assurance, and documentation, ensuring adherence to national and international standards. His previous role as Technical Manager involved the implementation and maintenance of ISO-17025 and GLP standards, critical for maintaining laboratory accuracy and reliability. Dr. Farid’s extensive experience also includes managing laboratory equipment procurement and validation, as well as training staff on analytical techniques and quality protocols. His contributions to policy development and regulatory practices highlight his leadership and commitment to advancing industry standards. His career trajectory, from Drug Quality Control Specialist to Associate Professor, reflects a deep and evolving expertise, underpinned by a dedication to both scientific excellence and professional development.

Research Skill

Dr. Omar Abdel-Hamed Ahmed-Farid possesses a robust set of research skills, underscored by his extensive experience and academic background. His proficiency in analytical techniques such as High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Spectrophotometry highlights his capability to conduct precise and comprehensive biochemical analyses. Dr. Farid has demonstrated expertise in determining neurotransmitters, amino acids, and cellular metabolites, utilizing advanced methods like Atomic Absorption Spectroscopy and ELISA techniques. His research includes investigating enzymatic and non-enzymatic antioxidants, analyzing tissue samples using the Comet Assay, and studying animal blood pressure. His ability to apply complex analytical methods and maintain high standards in research protocols is further evidenced by his contributions to method validation and compliance with international standards. Dr. Farid’s analytical skills, combined with his commitment to quality and innovation, underscore his exceptional research capabilities.

Award and Recognition

Dr. Omar Abdel-Hamed Ahmed-Farid has demonstrated exceptional expertise and dedication in the field of physiology and analytical chemistry, earning widespread recognition for his impactful research and professional contributions. With 1889 citations, an H-index of 24, and a Researchgate score of 46.42, his scholarly work has significantly influenced the scientific community. As the Unit Administration Manager at the Egyptian Drug Authority, Dr. Farid has excelled in ensuring regulatory compliance, maintaining high-quality standards, and leading a team dedicated to advancing diagnostic practices. His commitment to policy development, training, and innovation underscores his role as a pivotal figure in the industry. Dr. Farid’s achievements reflect a remarkable blend of academic excellence and practical impact, making him a distinguished candidate for the Research for Best Researcher Award.

Conclusion

Dr. Omar Abdel-Hamed Ahmed-Farid’s comprehensive research contributions, extensive professional experience, and leadership in regulatory and quality assurance roles make him a highly suitable candidate for the Research for Best Researcher Award. His impact on the field through his research, coupled with his commitment to advancing regulatory practices and training, aligns well with the criteria for this prestigious award.

Publication Top Notes

  • Publication Title: Recombinant Interleukin − 2 Immunotherapy Ameliorates Inflammation and Promotes the Release of Monoamine Neurotransmitters in the Gut-Brain Axis of Schistosoma mansoni-Infected Mice
    • Authors: Mehran, H.S., Nady, S., Kassab, R.B., Ahmed-Farid, O.A., El-Hennamy, R.E.
    • Journal: Journal of Neuroimmune Pharmacology
    • Year: 2024
    • Volume: 19
    • Issue: 1
    • Pages: 37
    • Citations: 0
  • Publication Title: Anti-depressant effect of Naringenin-loaded hybridized nanoparticles in diabetic rats via PPARγ/NLRP3 pathway
    • Authors: El-Marasy, S.A., AbouSamra, M.M., Moustafa, P.E., Galal, A.F., Farouk, H., Ahmed-Farid, O.A.
    • Journal: Scientific Reports
    • Year: 2024
    • Volume: 14
    • Issue: 1
    • Article Number: 13559
    • Citations: 0
  • Publication Title: The study of wound healing activity of Thespesia populnea L. bark, an approach for accelerating healing through nanoparticles and isolation of main active constituents
    • Authors: Abdel Halim, M.B., Eid, H.H., El Deeb, K.S., Ahmed-Farid, O.A., El Messiry, H.M.
    • Journal: BMC Complementary Medicine and Therapies
    • Year: 2024
    • Volume: 24
    • Issue: 1
    • Article Number: 85
    • Citations: 0
  • Publication Title: Eugenol alleviates acrylamide-induced rat testicular toxicity by modulating AMPK/p-AKT/mTOR signaling pathway and blood–testis barrier remodeling
    • Authors: Saleh, D.O., Baraka, S.M., Jaleel, G.A.A., Hassan, A., Ahmed-Farid, O.A.
    • Journal: Scientific Reports
    • Year: 2024
    • Volume: 14
    • Issue: 1
    • Article Number: 1910
    • Citations: 1
  • Publication Title: Gastro-Protective, Antioxidant, and Anti-Inflammatory Potential of Three Vegetable Oils Against Indomethacin-Induced Gastric Ulceration in Rats: in Vivo and in Vitro Study
    • Authors: Mohamed, M.M., Ahmed-Farid, O.A.
    • Journal: Egyptian Journal of Chemistry
    • Year: 2024
    • Volume: 67
    • Issue: 7
    • Pages: 341–359
    • Citations: 0
  • Publication Title: A combined administration of GABA agonist and L-histidine synergistically alleviates obesity-induced neuro-lipotoxicity and distorted metabolic transcriptome
    • Authors: Al-Malki, E.S., Ahmed-Farid, O.A., Moustafa, M.M.A., Linhardt, R.J., Warda, M.
    • Journal: Scientific African
    • Year: 2024
    • Volume: 24
    • Article Number: e02177
    • Citations: 0
  • Publication Title: Tolerability of Artemisia absinthium in anorexia: Targeting of neuronal appetite and satiety in zinc deficiency diet rat model
    • Authors: El-bakry, K.A.-E.K.M., Bahnasawy, M.H., Deef, L.E., Ahmed-Farid, O.A.-H., El-Naeli, S.S.B.
    • Journal: Scientific African
    • Year: 2024
    • Volume: 24
    • Article Number: e02162
    • Citations: 0
  • Publication Title: Zinc Oxide Nanoparticles Attenuated Neurochemical and Histopathological Alterations Associated with Aluminium Chloride Intoxication in Rats
    • Authors: Attia, F.M., Kassab, R.B., Ahmed-Farid, O.A., Abdel Moneim, A.E., El-Yamany, N.A.
    • Journal: Biological Trace Element Research
    • Year: 2024
    • Volume: (in press)
    • Citations: 0
  • Publication Title: Neurological study on the effect of CeNPs and/or La Cl3 on adult male albino rats
    • Authors: Abdel-Rahman, M., Elmasry, H.M., Ahmed-Farid, O.A., Hegazy, S.M., Rezk, M.M.
    • Journal: Journal of Trace Elements in Medicine and Biology
    • Year: 2024
    • Volume: 81
    • Article Number: 127323
    • Citations: 2
  • Publication Title: Nanoliposomal amino acids counteracting protein malnutrition induced hematopoietic and hepatic complications
    • Authors: Ahmed, R.F., Elbaset, M.A., Farouk, H., Ahmed-Farid, O.A.H., Nasr, M.
    • Journal: Journal of Drug Delivery Science and Technology
    • Year: 2023
    • Volume: 89
    • Article Number: 105051
    • Citations: 0

 

Xian Zheng | Pharmaceutical Science | Best Researcher Award

Posted on by ScienceFather

Dr. Xian Zheng | Pharmaceutical Science | Best Researcher Award

Assistant research Fellow of Affiliated Kunshan Hospital of Jiangsu University, China.

Xian Zheng is a prominent researcher specializing in Chinese herbal drugs, natural products, and nonalcoholic fatty liver disease (NAFLD). With a Ph.D. in Chinese pharmacy from China Pharmaceutical University, he currently serves as an Assistant Researcher at the Affiliated Kunshan Hospital of Jiangsu University and a part-time postdoctoral researcher at the Suzhou Institute of Nano-tech and Nano-bionics. Zheng leads several high-impact projects, including studies on arjunolic acid and liposome-based therapies for NAFLD, supported by major funding bodies like the National Natural Science Foundation of China. His research is well-regarded, with numerous publications in leading journals such as Phytomedicine and J Functional Foods. Zheng has been honored with awards like Jiangsu Double Innovation Doctor and Gusu Health Talents Plan-“Class D special talents”. His work showcases significant contributions to the field, marked by a strong publication record and leadership in innovative research.

Profile
Education

Xian Zheng’s educational background reflects a strong foundation in pharmacology and pharmacy. He earned his Ph.D. in Chinese Pharmacy from the College of Traditional Chinese Medicine at China Pharmaceutical University, Nanjing, in December 2021, under the supervision of Professor Zhiqi Yin. Prior to this, he completed his Master of Science in Pharmacology at the School of Pharmacy, Xuzhou Medical University, in June 2018, guided by Professor Yi Liu. Zheng’s academic journey began with a Ph.D. in Pharmacy from the School of Pharmacy, Nanjing2 University of Chinese Medicine, which he completed in June 2015. This extensive education, encompassing both traditional Chinese medicine and modern pharmacology, has provided him with a robust understanding of drug development and therapeutic applications, particularly in the realm of natural products and their effects on nonalcoholic fatty liver disease.

Professional Experience

Xian Zheng currently serves as an Assistant Researcher at the Department of Pharmacy, Affiliated Kunshan Hospital of Jiangsu University, where he has been contributing to cutting-edge research since February 2022. Additionally, he is a part-time postdoctoral researcher at the Suzhou Institute of Nano-tech and Nano-bionics, a position he has held since October 2022. Zheng’s professional journey includes significant achievements in studying Chinese herbal drugs and natural products, particularly in the context of nonalcoholic fatty liver disease (NAFLD). He leads multiple high-profile research projects funded by prestigious organizations such as the National Natural Science Foundation of China and the Gusu Health Talent Research Project. His expertise in pharmacology and his leadership in these research initiatives highlight his dedication and impact in advancing therapeutic strategies for NAFLD and related conditions.

Research Interest

Xian Zheng’s research interests primarily focus on Chinese herbal drugs and natural products, with a particular emphasis on their therapeutic potential for nonalcoholic fatty liver disease (NAFLD). His work explores innovative treatment approaches, such as the dual NAMPT activation theory, and the development of liposome-based drug delivery systems to enhance the efficacy of herbal compounds. Zheng’s research aims to uncover the underlying mechanisms of these treatments, such as their effects on metabolic pathways and cellular functions. He is dedicated to advancing the understanding of how traditional herbal remedies can be optimized and integrated into modern therapeutic strategies for complex liver diseases. By combining traditional pharmacological insights with contemporary biomedical techniques, Zheng seeks to bridge the gap between ancient remedies and modern medicine, ultimately improving clinical outcomes for patients with NAFLD and contributing to the broader field of natural product research.

Research Skills

Xian Zheng demonstrates exceptional research skills, particularly in the domain of pharmacology and natural product research. His expertise encompasses a comprehensive understanding of Chinese herbal drugs and their therapeutic applications, with a specific focus on nonalcoholic fatty liver disease (NAFLD). Zheng excels in designing and leading innovative research projects, such as exploring dual NAMPT activation and developing liposome-based therapies for NAFLD. His ability to secure funding from prestigious organizations, including the National Natural Science Foundation of China, underscores his proficiency in research proposal development and project management. Zheng’s analytical skills are evident in his extensive publication record in reputable journals, where he contributes to advancing knowledge in his field. His role as a part-time postdoctoral researcher further reflects his commitment to scientific inquiry and collaboration. Overall, Zheng’s research skills are marked by a blend of innovative thinking, effective project leadership, and a strong publication track record.

Awards and Recognition

Xian Zheng has earned notable recognition in his field through a series of prestigious awards and honors. His achievements include being named a Jiangsu Double Innovation Doctor, which acknowledges his exceptional contributions to innovative research in Chinese pharmacy. Additionally, Zheng is distinguished as a “Class D special talents” under the Gusu Health Talents Plan, underscoring his impactful work in the realm of natural products and nonalcoholic fatty liver disease. He was also recognized as a Kunshan Youth Post Expert in 2022 and a Suzhou Youth Post Expert in 2023, highlighting his significant contributions to the scientific community and his leadership in advancing research. These accolades reflect Zheng’s dedication and impact in the field of pharmacology and his commitment to advancing therapeutic approaches through his innovative research efforts.

Conclusion

Dr. Tao Song is a strong candidate for the Best Researcher Award due to his significant contributions to the field of catalysis and green chemistry. His innovative research and high-impact publications demonstrate a clear potential for future leadership in the field. To further strengthen his candidacy, Dr. Song could focus on expanding the impact of his research through interdisciplinary collaborations and leadership roles. Given his achievements and potential, Dr. Song is well-suited for recognition as a leading researcher in his field.

Publications Top Notes

  1. Arjunolic Acid from Cyclocarya paliurus Selectively Inhibits Glucagon Secretion from α Cells and Ameliorates Diabetes via Ephrin-A1 and EphA4 Interaction
    • Authors: Fang, C.-Q., Teng, Y., Wang, Y.-T., Cao, X.-L., Jiang, C.-H.
    • Year: 2022
  2. Aloin A Prevents Ulcerative Colitis in Mice by Enhancing the Intestinal Barrier Function via Suppressing the Notch Signaling Pathway
    • Authors: Jiang, H., Shi, G.-F., Fang, Y.-X., Zhang, J., Yin, Z.-Q.
    • Year: 2022
    • Citations: 11
  3. Protective Effects of Cyclocarya paliurus on Hyperuricemia and Urate-Induced Inflammation
    • Authors: Zhu, L.-H., Xu, Y.-Y., Zhu, L.-P., Zhang, J., Yin, Z.-Q.
    • Year: 2022
    • Citations: 9
  4. Cyclocarya paliurus Triterpenoids Attenuate Glomerular Endothelial Injury in Diabetic Rats via ROCK Pathway
    • Authors: Yang, R., Xu, S., Zhang, X., Yin, Z., Pan, K.
    • Year: 2022
    • Citations: 8
  5. Chrysin Inhibits Hepatocellular Carcinoma Progression Through Suppressing Programmed Death Ligand 1 Expression
    • Authors: Rong, W., Wan, N., Zheng, X., Gao, Z.-J., Zhang, J.
    • Year: 2022
    • Citations: 17
  6. New Dammarane-Type Triterpenoid Saponins from Gynostemma pentaphyllum and Their Sirt1 Agonist Activity
    • Authors: Lou, Y.-Y., Zheng, X., Huang, Y.-P., Yin, Z.-Q., Pan, K.
    • Year: 2021
    • Citations: 12
  7. Arjunolic Acid from Cyclocarya paliurus Ameliorates Nonalcoholic Fatty Liver Disease in Mice via Activating Sirt1/AMPK, Triggering Autophagy and Improving Gut Barrier Function
    • Authors: Zheng, X., Zhang, X.-G., Liu, Y., Zhang, J., Yin, Z.-Q.
    • Year: 2021
    • Citations: 6
  8. Aloe Vera Mitigates Dextran Sulfate Sodium-Induced Rat Ulcerative Colitis by Potentiating Colon Mucus Barrier
    • Authors: Shi, G., Jiang, H., Feng, J., Jiang, C., Zhang, J.
    • Year: 2021
    • Citations: 30
  9. Four New Dammarane Triterpenoid Glycosides from the Leaves of Cyclocarya paliurus and Their SIRT1 Activation Activities
    • Authors: Zhu, L.-P., Yang, H.-M., Zheng, X., Zhang, J., Yin, Z.-Q.
    • Year: 2021
    • Citations: 7
  10. Gypenoside LVI Improves Hepatic LDL Uptake by Decreasing PCSK9 and Upregulating LDLR Expression
    • Authors: Wang, J., Wang, Y.-S., Huang, Y.-P., Yin, Z.-Q., Zhang, J.
    • Year: 2021
    • Citations: 21